Intensity Therapeutics, Inc.
INTS
$1.85
-$0.01-0.54%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.31% | 24.58% | 316.02% | 301.67% | 166.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.45% | 43.32% | 315.15% | 278.23% | 127.44% |
| Operating Income | 4.45% | -43.32% | -315.15% | -278.23% | -127.44% |
| Income Before Tax | -0.28% | -50.84% | -34.32% | -244.54% | -110.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.28% | -50.84% | -34.32% | -244.54% | -110.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.28% | -50.84% | -34.32% | -244.54% | -110.01% |
| EBIT | 4.45% | -43.32% | -315.15% | -278.23% | -127.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 4.12% | -49.27% | 74.63% | 14.29% | 47.98% |
| Normalized Basic EPS | 4.10% | -49.16% | 11.42% | 14.33% | 47.98% |
| EPS Diluted | -91.84% | -49.27% | 74.63% | 14.29% | 47.98% |
| Normalized Diluted EPS | 4.10% | -49.16% | 11.42% | 14.33% | 47.98% |
| Average Basic Shares Outstanding | 4.62% | 1.05% | 289.93% | 302.03% | 303.66% |
| Average Diluted Shares Outstanding | 4.62% | 1.05% | 289.93% | 302.03% | 303.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |